
Neupogen Market, By Indication (Chemotherapy-induced neutropenia in non-myeloid malignancies, Neutropenia in acute myeloid leukemia (AmL) patients post induction or consolidation chemotherapy, Neutropenia post-myeloablative chemotherapy followed by bone m
Description
The global Neupogen market, while initially experiencing growth, is now facing a decline due to several factors. Neupogen (filgrastim) is a recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the production of neutrophils, which are essential for fighting infections. It is primarily used to prevent and treat neutropenia, a condition often induced by chemotherapy or radiation therapy. However, despite its effectiveness, the market is now shrinking. The market is declining due to several challenges, including the high cost of Neupogen, which limits its accessibility, particularly in low- and middle-income countries. Furthermore, the availability of biosimilars and alternative treatment options like pegfilgrastim and lenograstim have increased competition and reduced Neupogen's market share.
Market Dynamics
The market for Neupogen, while still benefiting from growing awareness about the importance of supportive care in cancer treatment, particularly in preventing febrile neutropenia and its complications, is experiencing slower growth. Despite ongoing research and development efforts to expand Neupogen’s indications and introduce innovative delivery systems, such as sustained-release formulations and transdermal patches, these advancements have not been sufficient to counterbalance the overall decline in market demand. While the aging population and rising cancer incidence continue to sustain some demand, cost-related factors and increasing competition are significantly impacting the market's growth trajectory. As a result, the Neupogen market is currently on a downward trend.
Key Features of the Study
Market Dynamics
The market for Neupogen, while still benefiting from growing awareness about the importance of supportive care in cancer treatment, particularly in preventing febrile neutropenia and its complications, is experiencing slower growth. Despite ongoing research and development efforts to expand Neupogen’s indications and introduce innovative delivery systems, such as sustained-release formulations and transdermal patches, these advancements have not been sufficient to counterbalance the overall decline in market demand. While the aging population and rising cancer incidence continue to sustain some demand, cost-related factors and increasing competition are significantly impacting the market's growth trajectory. As a result, the Neupogen market is currently on a downward trend.
Key Features of the Study
- This report provides an in-depth analysis of the global Neupogen market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global Neupogen market based on the following parameters: company highlights, product portfolio, key highlights, financial performance, and strategies
- Key company covered as a part of this study includes Amgen Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global Neupogen market report caters to various stakeholders in this industry, including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Neupogen market
- Indication Insights (Revenue, USD Mn, 2020 - 2032)
- Chemotherapy-induced neutropenia in non-myeloid malignancies
- Neutropenia in acute myeloid leukemia (AmL) patients post-induction or consolidation chemotherapy
- Neutropenia post-myeloablative chemotherapy followed by bone marrow transplantation (BMT)
- Mobilization of autologous hematopoietic progenitor cells for leukapheresis
- Chronic neutropenia (congenital, cyclic, idiopathic)
- Hematopoietic Syndrome of Acute Radiation Syndrome (H-ARS)
- Dose Strength Insights (Revenue, USD Mn, 2020 - 2032)
- 300mcg/1mL
- 480mcg/1.6mL
- 300MGC/0.5mL
- 480mcg/0.8mL
- Packaging Insights (Revenue, USD Mn, 2020 - 2032)
- Single-use vials
- Prefilled syringes
- Patient Age Group Insights (Revenue, USD Mn, 2020 - 2032)
- Pediatric
- Adult
- Geriatric
- Sales Channel Insights (Revenue, USD Mn, 2020 - 2032)
- Online
- Offline
- End User Insights (Revenue, USD Mn, 2020 - 2032)
- Hospitals
- Oncology Clinics
- Ambulatory Surgical Centers
- Others (Academic & Research Institutions, etc.)
- Regional Insights (Revenue, USD Mn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Amgen Inc.
Table of Contents
165 Pages
- 1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Neupogen Market, By Indication
- Global Neupogen Market, By Dose Strength
- Global Neupogen Market, By Packaging
- Global Neupogen Market, By Patient Age Group
- Global Neupogen Market, By Sales Channel
- Global Neupogen Market, By End User
- Global Neupogen Market, By Region
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER’s Analysis
- Merger and Acquisition Scenario
- Industry Trends
- Reimbursement Scenario
- Epidemiology
- Pricing Analysis
- 4. Global Neupogen Market, By Indication, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Chemotherapy-induced neutropenia in non-myeloid malignancies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Neutropenia in acute myeloid leukemia (AML) patients post-induction or consolidation chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Neutropenia post-myeloablative chemotherapy followed by bone marrow transplantation (BMT)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Mobilization of autologous hematopoietic progenitor cells for leukapheresis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Chronic neutropenia (congenital, cyclic, idiopathic)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Hematopoietic Syndrome of Acute Radiation Syndrome (H-ARS)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- 5. Global Neupogen Market, By Dose Strength, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- 300mcg/1mL
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- 480mcg/1.6mL
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- 300MGC/0.5mL
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- 480mcg/0.8mL
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- 6. Global Neupogen Market, By Packaging, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Single-use vials
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Prefilled syringes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- 7. Global Neupogen Market, By Patient Age Group, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- 8. Global Neupogen Market, By Sales Channel, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Online
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Offline
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- 9. Global Neupogen Market, By End User, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Oncology Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Others (Academic & Research Institutions, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- 10. Global Neupogen Market, By Region, 2020 - 2032, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Dose Strength, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Packaging, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Dose Strength, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Packaging, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Dose Strength, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Packaging, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Dose Strength, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Packaging, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Dose Strength, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Packaging, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Dose Strength, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Packaging, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
- 11. Competitive Landscape
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- 12. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
- 13. References and Research Methodology
- References
- Research Methodology
- About us
- *Browse 32 market data tables and 28 figures on ‘Neupogen Market' - Global forecast to 2032
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.